Guidelines for Establishing Safety in Ayahuasca and Ibogaine Administration in Clinical Settings

Rocha, Juliana M., Reis, José Augusto S., Rossi, Giordano N., Bouso, José Carlos, Hallak, Jaime E. C., dos Santos, Rafael G. · 2023 · Psychoactives

AI-extracted · unverified · confirm at source

USP/LEAPS clinical protocols: ECG and electrolyte screening required (thresholds deferred to cited guidelines), 72h monitoring endorsed per GITA, medication tapering schedules, 3-person minimum team, trauma-informed approach framework.

Dosing: Not specified (not-specified)

Contraindications: Personal or family history of psychosis, bipolar disorder, or schizophrenia, Recent cardiac, renal, or hepatic pathology (note: 'recent' is not defined by the paper), Pregnancy or lactation, Concurrent uncontrolled psychotropic medication use, Severe dissociative symptoms or severe personality disorders, Active suicidality requiring pharmacological treatment, Manic episodes (current or historical, including antidepressant-induced), Drug-induced psychosis history, Uncontrolled general medical pathologies